North America to Lead in Opioid Induced Constipation Treatment Market 

The number of patients suffering from opioid induced constipation has reached an alarming rate. In the U.S. alone, close to 100 mn patients were diagnosed to suffer from OIC in 2013 as per a report by the American Academy of Pain Medicine. The number is expected to increase with an increase in the number of people consuming opioid drugs. The commercial availability of opioid drugs has led to a large number of patients using them for treating chronic pains. According to a report published by Transparency Market Research (TMR), the global market for opioid induced constipation treatment is expected to rise from US$731.2 mn in 2016 to reach US$4.81 bn by the end of 2023. The market is expected to exhibit a stupendous CAGR of 31.2% from 2015 to 2023. 

Given below are answers to three vital questions pertaining to the global opioid induced constipation treatment market, answered by TMR experts. 

Q. Which drug class is expected to emerge as most popular in the years to come?

In 2016, the chloride channel activators was the most popular drug class of opioid induced constipation treatments on account of the high sales of Amitiza. The demand for chloride channel activators will continue to rise, however, the mu-opioid receptor antagonists segment will lead in the coming years. The greater efficacy of mu-opioid receptor antagonists and the growing number of approval for this drug class is expected to be the reason for the growth of this segment. The growing number of prescriptions being filed for opioid induced constipation treatments as they have less side effects will also be a reason for the demand of this drug class. 


Q. Which region will prove to be most lucrative in the opioid induced constipation treatment market?

North America is not only leading at present but is estimated to continue to lead in the years to come. The legal acceptance of opioids for pain treatment in the U.S. is expected to be a key reason behind the growth of the market in the region. The high number of patients suffering from opioid induced constipation in the region will be a key reason for the growth of the North American OIC treatment market. It is estimated that North America will generate US$4.05 bn in revenue by 2023. Other regions have very low awareness rates of available opioid induced constipation treatments. This is also another reason for the growth of North American opioid induced constipation treatment market.

Q. What is the biggest challenge hampering the growth of the global opioid induced constipation treatment market?

One of the biggest challenges for the global opioid induced constipation treatment market is the widespread use of laxatives for treatment. The high price of opioid induced constipation treatment drugs is expected to be a key challenge for the growth of this market. The price of standard laxatives is much cheaper and this disparity in pricing between standard laxatives and OIC treatment drugs will be a major challenge for the market’s growth. In addition to this, many of the opioid induced constipation treatment drugs cause side effects such as nausea and increase the risk of heart problems and strokes, posing another challenge.

0 comments:

Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports